Rituximab binds CD20 on B cells and recruits effector mechanisms—ADCC via Fcγ receptor–bearing cells (e.g., NK cells) and complement-dependent cytotoxicity via C1q activation—resulting in lysis/apoptosis of CD20+ cells.